Hereditary Angioedema Pipeline Summary

DelveInsight’s, “Hereditary Angioedema - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hereditary Angioedema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hereditary Angioedema: Understanding

Hereditary Angioedema: Overview

Hereditary angioedema (HAE) is a rare, autosomal dominant genetic disorder characterized by recurrent episodes of non-pruritic, non-pitting subcutaneous and submucosal edema involving the skin, gastrointestinal tract, and upper airway. Most cases are caused by pathogenic variants in the SERPING1 gene, resulting in deficiency (type I) or dysfunction (type II) of C1 esterase inhibitor (C1-INH), while HAE with normal C1-INH is associated with mutations in genes such as F12, PLG, ANGPT1, KNG1, MYOF, or HS3ST6. Attacks may be triggered by physical trauma, emotional stress, infections, hormonal changes, or medical and dental procedures.

Clinical manifestations include recurrent swelling of the extremities, face, genitalia, severe abdominal pain with nausea and vomiting due to gastrointestinal edema, and potentially life-threatening laryngeal edema causing airway obstruction. Because HAE is bradykinin-mediated rather than histamine-mediated, it does not respond to antihistamines, corticosteroids, or epinephrine.

The pathophysiology of HAE centers on uncontrolled activation of the plasma kallikrein–kinin system, resulting from inadequate functional C1-INH. Loss of C1-INH activity permits excessive activation of factor XII and plasma kallikrein, leading to increased production of bradykinin, which binds to bradykinin B2 receptors on vascular endothelial cells and causes increased vascular permeability and localized edema.

Diagnosis is based on a compatible clinical history, family history, and laboratory confirmation demonstrating low C4 levels together with reduced quantitative or functional C1-INH levels in types I and II HAE. Genetic testing may be performed to identify SERPING1 or other disease-associated variants, particularly in patients with normal C1-INH or uncertain diagnoses. Early diagnosis is essential because delayed recognition may increase the risk of recurrent severe attacks and fatal airway compromise.

Management of HAE includes on-demand treatment of acute attacks, short-term prophylaxis before high-risk procedures, and long-term prophylaxis for patients with frequent or severe attacks. Acute attacks are treated with plasma-derived or recombinant C1-INH concentrates, the bradykinin B2 receptor antagonist icatibant, or the plasma kallikrein inhibitor ecallantide, depending on regional availability. Long-term prophylaxis includes subcutaneous C1-INH replacement, the monoclonal antibody lanadelumab, and the oral plasma kallikrein inhibitor berotralstat, all of which significantly reduce attack frequency. Patients should receive individualized treatment plans, education regarding early recognition of laryngeal attacks, access to emergency therapy, and genetic counseling, while emerging gene therapies and RNA-targeted approaches are being investigated as potential disease-modifying treatments.

"Hereditary Angioedema- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hereditary Angioedema pipeline landscape is provided which includes the disease overview and Hereditary Angioedema treatment guidelines. The assessment part of the report embraces, in depth Hereditary Angioedema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hereditary Angioedema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hereditary Angioedema R&D. The therapies under development are focused on novel approaches to treat/improve Hereditary Angioedema.

Hereditary Angioedema Emerging Drugs Chapters

This segment of the Hereditary Angioedema report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hereditary Angioedema Emerging Drugs

ADX-324: ADARx Pharmaceuticals

ADX-324 (onvuzosiran) is an investigational, long-acting small interfering RNA (siRNA) therapeutic being developed by ADARx Pharmaceuticals for the prophylactic treatment of hereditary angioedema (HAE) types I and II. It works by selectively silencing prekallikrein (PKK) production in the liver, thereby reducing bradykinin generation, the key mediator of HAE attacks. ADX-324 is designed for infrequent subcutaneous dosing with the potential for twice-yearly administration, aiming to provide durable prevention of HAE attacks. The candidate is currently being evaluated in the Phase III STOP-HAE randomized, placebo-controlled trial to assess its efficacy, safety, pharmacokinetics, pharmacodynamics, and quality-of-life outcomes.

Further product details are provided in the report……..

Hereditary Angioedema: Therapeutic Assessment

This segment of the report provides insights about the different Hereditary Angioedema drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hereditary Angioedema
• There are approx. 10+ key companies which are developing the therapies for Hereditary Angioedema. The companies which have their Hereditary Angioedema drug candidates in the most advanced stage, i.e. Phase III include, ADARx Pharmaceuticals.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Hereditary Angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hereditary Angioedema: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Hereditary Angioedema therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hereditary Angioedema drugs.

Hereditary Angioedema Report Insights

• Hereditary Angioedema Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hereditary Angioedema Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hereditary Angioedema drugs?
• How many Hereditary Angioedema drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hereditary Angioedema?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hereditary Angioedema therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hereditary Angioedema and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ADARx Pharmaceuticals
• BioCryst Pharmaceuticals
• Argo Biopharma
• Intellia Therapeutics, Inc.
• Octa Pharma

Key Products

• ADX-324
• Navenibart
• BW-20805
• Lonvoguran ziclumeran
• OCTA-C1-INH